Aura BiosciencesAURA
About: Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Employees: 106
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
138% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 16
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
16% more funds holding
Funds holding: 81 [Q3] → 94 (+13) [Q4]
4.56% more ownership
Funds ownership: 74.42% [Q3] → 78.98% (+4.56%) [Q4]
2% less capital invested
Capital invested by funds: $330M [Q3] → $324M (-$5.39M) [Q4]
94% less call options, than puts
Call options by funds: $16K | Put options by funds: $255K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Citizens Capital Markets Jonathan Wolleben 0 / 0 met price target | 235%upside $19 | Market Outperform Maintained | 26 Mar 2025 |
HC Wainwright & Co. Edward White 27% 1-year accuracy 40 / 149 met price target | 341%upside $25 | Buy Maintained | 25 Mar 2025 |
Financial journalist opinion
Based on 4 articles about AURA published over the past 30 days









